Caplyta may expand from bipolar depression into acute mania

Caplyta’s role could broaden from bipolar depression to covering both poles of bipolar I disorder—depression and acute mania—if the FDA accepts J&J’s eventual filing.

The first pivotal Phase III mania study met its primary endpoint:
42 mg once daily reduced Young Mania Rating Scale scores by 4.8 points more than placebo at Week 3, with separation beginning by Day 3. Clinical response was 45.8% versus 20.9% for placebo.

J&J says a second pivotal Phase III mania study has been completed and is being analyzed. The company is expected to discuss a regulatory submission with the FDA, but Caplyta is not yet approved for bipolar mania.

If approved, rapid symptom improvement and Caplyta’s existing profile in bipolar depression could support use as a single branded option across acute phases, potentially reducing reliance on switching between drugs. Actual uptake will depend on the second study, full safety data, labeling, and comparisons with established antimanic therapies.

The reported adverse-event signal was relatively limited in the topline release; dry mouth and nausea were the main treatment-related events reported at least twice as often as placebo. Longer-term and mania-specific safety data remain important, especially because acute mania treatment often involves severely ill or hospitalized patients.